FOR IMMEDIATE RELEASE: Seattle | Oct. 5, 2017: IDRI (Infectious Disease Research Institute) is part of a new consortium formed to prepare and test a vaccine formulation designed to protect against the Ebola, Sudan, Marburg, and Lassa fever viruses. If successful, this would be the first vaccine to induce protection against four different hemorrhagic fever viruses, which can damage blood vessels, cause internal bleeding and result in high mortality rates, as seen in the West African Ebola outbreak. The consortium is led by Thomas Jefferson University, which received a contract from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. NIAID has made an initial award of about $2.6 million to Thomas Jefferson University
with further funding of up to a total of $30 million available over the course of the contract if all contract options are exercised.
“Bringing this type of large consortium together to lend individual areas of expertise is the pathway to more effective vaccine development,” said Dan Stinchcomb, PhD, IDRI’s Chief Scientific Officer. “IDRI is pleased to provide formulation and adjuvant expertise that was critical for the vaccine to demonstrate complete protection from Ebola virus in preclinical models.”
“Our approach is to create a broad scope of coverage with a tetravalent vaccine—one that covers four of these deadly viral diseases,” said Principal Investigator Matthias Schnell, Ph.D., Professor and Chair of Microbiology and Immunology and Director of the Jefferson Vaccine Center at the Sidney Kimmel Medical College at Thomas Jefferson University.
If successful, the tetravalent vaccine could have the added advantage of protecting against the deadly rabies virus. Since the vaccine will be an inactivated, or killed, virus formulation, it cannot cause infection and has the potential to be safe for all populations, including immune-compromised individuals, pregnant women and young children.
Dr. Schnell, who is also the Director of the World Health Organization (WHO) Collaborating Centre for Neurovirology, will lead the project team, composed of experts in the field of vaccine development and testing. “A project of this size can benefit significantly from a broad range of vaccine expertise, resulting in the timely development, formulation, testing, and manufacturing of a new and novel vaccine product,” says Dr. Schnell.
The project team is composed of representatives from IDT Biologika GmbH, to develop the manufacturing process, and manufacture the vaccine; the Infectious Disease Research Institute (IDRI) and Immune Design, to develop the adjuvant component that will boost the vaccine’s potency; Exxell BIO, Inc., to assist in the clinical trial strategy and testing; and the US Army Medical Research Institute of Infectious Diseases (USAMRIID), together with The Geneva Foundation, to evaluate the safety and efficacy of the completed vaccine prior to human use.
This five-year contract, with the goal of completing a Phase 1 clinical trial of the tetravalent vaccine, will be funded by NIAID under Contract No. HHSN272201700082C.
About IDRI: As a nonprofit global health organization, IDRI (Infectious Disease Research Institute) takes a comprehensive approach to combat infectious diseases, combining the high-quality science of a research organization with the product development capabilities of a biotech company to create new diagnostics, drugs and vaccines. Founded in 1993, IDRI has 125 employees headquartered in Seattle with nearly 100 partners/collaborators around the world. For more information, visit www.idri.org.
IDRI: Lee Schoentrup | 206.858.6064 | email@example.com